Other
Radiodermatitis
13
Pipeline Programs↗
0
Active Trials↗
6
Companies Involved↗
Radiodermatitis is an emerging landscape with 13 programs across 6 companies. The most active players are Merck & Co., Novartis, Pfizer. 4 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 25
Phase 33
Analysis
Trial Status
9
clinical trials
Completed5 · 56%
Unknown status3 · 33%
Terminated1 · 11%
Clinical Trials
Trial Activity
9 trials
Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients
Completed·—·Phase 4·NCT05285943·132 enrolled
Phase III Trial Evaluating Radium Bromatum Homeopathic Treatment Efficacy on Radiodermatitis Prevention and Treatment for Breast Cancer Women
Completed·—·Phase 3·NCT03753776·232 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)